<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02389595</url>
  </required_header>
  <id_info>
    <org_study_id>IRB201401012-N</org_study_id>
    <secondary_id>5R01AI030904</secondary_id>
    <nct_id>NCT02389595</nct_id>
  </id_info>
  <brief_title>A T Cell-based HIV Vaccine</brief_title>
  <official_title>Selection of a Protective T Cell-based HIV-1/FIV Vaccine Devoid of Viral Enhancing Epitopes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janet K. Yamamoto Donor Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to develop a vaccine against Human immunodeficiency&#xD;
      virus (HIV), a disease that causes AIDS in people,. The investigator will be looking at&#xD;
      viruses similar to HIV in animals. Since these viruses are very similar to HIV, the blood&#xD;
      from humans who have been exposed to HIV will be tested to see if the immune system will&#xD;
      recognize the HIV and prevent infection.&#xD;
&#xD;
      HIV targets the immune system by attacking certain T cells called CD4+ T cells. There are&#xD;
      parts on the AIDS viruses that help the virus infect these cells and other parts that help&#xD;
      the immune system prevent viral infection by activating protective T-cells that fight HIV.&#xD;
      Different T-cell populations are very important in most vaccines as they act as &quot;effectors&quot;&#xD;
      that work as part of the immune system to recognize and fight off HIV infection. When&#xD;
      effector T cells are activated by appropriate &quot;protective&quot; part(s) of the virus they either&#xD;
      block HIV from reproducing or kill HIV infected cells. By finding these common protective&#xD;
      parts of each of these human and animal AIDS viruses, the investigator hopes to make a&#xD;
      vaccine that helps the immune system prevent HIV infection by avoiding parts that attack CD4+&#xD;
      T cells and may worsen HIV infection and selecting for parts that stimulate effector T cells&#xD;
      that fight HIV infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As a participant in this study a blood drawn will performed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 2015</start_date>
  <completion_date type="Anticipated">May 2024</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>T cell proliferation in response to viral epitopes</measure>
    <time_frame>120 hours (5 days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cytokine production in response to viral epitopes</measure>
    <time_frame>24 hours (1 day)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytotoxin production in response to viral epitopes</measure>
    <time_frame>8 hours</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">270</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>HIV positive subjects</arm_group_label>
    <description>This group will provide a blood sample.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-infected control subjects</arm_group_label>
    <description>This group consist of de-identified blood samples from a commercial source.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>HIV positive subjects</intervention_name>
    <description>This group will provide a blood sample.</description>
    <arm_group_label>HIV positive subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non-infected control subjects</intervention_name>
    <description>This group will be de-identified blood samples from a commercial source.</description>
    <arm_group_label>Non-infected control subjects</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum Whole Blood T cells&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        HIV positive individuals between 18 and 65 years old&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female subjects between 18 and 65 years old who are HIV positive&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Persons with other immune diseases that would result in autoimmunity or aberrant&#xD;
             immune responses (such as subjects who have undergone chemotherapy within the past&#xD;
             year).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janet K Yamamoto, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Janet K Yamamoto, PhD</last_name>
    <phone>352-294-4145</phone>
    <email>yamamoto@ufl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alek Aranyos</last_name>
    <phone>352-294-4196</phone>
    <email>aaranyos1@ufl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janet K Yamamoto, PhD</last_name>
      <phone>352-294-4145</phone>
      <email>yamamoto@ufl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Shannon R Roff, DVM</last_name>
      <phone>352-294-4152</phone>
      <email>shannon.roff@ufl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Janet K Yamamoto, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UF Center for AIDS Research Education and Service</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mobeen H Rathore, MD</last_name>
      <phone>904-224-3739</phone>
      <email>mobeen.rathore@jax.ufl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kathleen A Thoma, CCRA</last_name>
      <phone>904-224-3059</phone>
      <email>kathleen.thoma@jax.ufl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Janet K Yamamoto, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 10, 2015</study_first_submitted>
  <study_first_submitted_qc>March 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2015</study_first_posted>
  <last_update_submitted>February 11, 2021</last_update_submitted>
  <last_update_submitted_qc>February 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>vaccine</keyword>
  <keyword>T cell</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

